Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. It focuses on precision medicine approaches, integrating clinical data, biomarkers, and genomic markers to target patient subgroups in central nervous system diseases. The company's lead candidate, ANAVEX 2-73 (blarcamesine), is an oral therapy that activates SIGMAR1 and muscarinic receptors to restore cellular homeostasis, supporting autophagy and addressing protein buildup in conditions like Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia. Another key program, ANAVEX 3-71, targets similar receptors and shows potential against cognitive deficits, amyloid, tau pathologies, mitochondrial dysfunction, and neuroinflammation. Anavex Life Sciences Corp. advances these investigational oral therapies through clinical trials, emphasizing biomarker-driven development for diseases with high unmet needs, including other CNS disorders, pain, and certain cancers. Headquartered in New York, New York, and founded in 2004, the company operates in the biotechnology sector, contributing to innovative treatments in brain health.